



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/510,622

06/27/2005

Giulio Alessandri

47706

2850

1609

7590

03/14/2008

ROYLANCE, ABRAMS, BERDO & GOODMAN, L.L.P.

1300 19TH STREET, N.W.

SUITE 600

WASHINGTON,, DC 20036

EXAMINER

BARNHART, LORA ELIZABETH

ART UNIT

PAPER NUMBER

1651

MAIL DATE

DELIVERY MODE

03/14/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/510,622	Applicant(s) ALESSANDRI ET AL.	
	Examiner Lora E. Barnhart	Art Unit 1651	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 December 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-14 is/are pending in the application.
- 4a) Of the above claim(s) 3-6 and 10-14 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,2 and 7-9 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>10/8/04, 5/2/07</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

Applicant's election without traverse of Group I, claims 1-5 and 7-9, in the reply filed on 12/11/07 is acknowledged. Applicant's further election without traverse of the species "human adipose tissue" in the same reply is acknowledged.

Claims 6 and 10-14 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 3-5 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 12/11/07.

Examination on the merits will commence at this time on claims 1, 2, and 7-9 ONLY, to the extent they read on the elected species where applicable.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 2, and 7-9 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The factors to be considered in determining whether undue experimentation is required are summarized in *In re Wands*, 858 F.2d 731, 737, 8 USPQd 1400, 1404 (Fed. Cir. 1988) (a) the breadth of the claims; (b) the nature of the invention; (c) the state of the prior art; (d) the level of one of ordinary skill; (e) the level of predictability in the art; (f) the amount of direction provided by the inventor; (g) the existence of working examples; and (h) the quantity of experimentation needed to make or use the invention based on the content of the disclosure. While all of these factors are considered, a sufficient number are discussed below so as to create a *prima facie* case.

The claims are drawn to a method of making stem cells by preparing a suspension of cells from human adipose tissue and culturing the cells in a medium comprising bovine serum albumin (BSA), four growth factors (bFGF, EGF, VEGF, and LIF), heparin, and other components. In some dependent claims, the amounts of components added to the media are particularly pointed out. In some dependent claims, the cells are incubated on a collagen-coated culture dish and then on a non-coated dish.

Adipose stromal cells were known at the time of the invention to be a source of stem cells. Zuk et al. (2002, *Molecular Biology of the Cell* 13: 4279-4295; IDS) teach washing lipoaspirate with PBS, treating said lipoaspirate with collagenase, and culturing the cells freed by the collagenase action in DMEM supplemented with FBS (page 4280 and Table 1).

Adding growth factors and other active agents to cultures of primary cells isolated from adipose is known to alter the differentiation state of the cells. Hauner et al. (2001,

Methods in Molecular Biology 155: 239-247; IDS) teach that culturing cells dissociated from adipose tissue in medium comprising insulin promotes differentiation of the cells to adipocytes (page 243, section 3.6, item 2). Hauner (2001) further teaches that incubating adipose stromal cells with FGF promotes adipocyte differentiation (page 243, section 3.5). Hauner et al. (1995, *European Journal of Clinical Investigation* 25: 90-96; IDS) teaches that EGF modulates the differentiation state of primary adipocyte precursor cells (page 90, column 2). Zhao et al. (1997, *Journal of Steroid Biochemistry and Molecular Biology* 61: 203-210; reference U) teach that LIF induces adipose stromal cells to begin synthesizing estrogen *in vitro* (Abstract and page 204, column 2). Amri et al. (1986, *Biochemical Journal* 238: 115-122; reference V) teach that putrescine promotes differentiation of adipose stromal cells to mature adipocytes (Abstract and Figure 1, e.g.). Investigations published after the instant filing indicate that the skilled artisan would not have had a reasonable expectation of using the instantly recited method to yield stem cells from adipose. Song et al. (2007, *Biochemical and Biophysical Research Communications* 354: 999-1003; reference W) teach that adipose stromal cells cultured in VEGF spontaneously differentiate into cardiomyocytes (Abstract and page 1003, column 1).

At the time of the invention, skilled artisans recognized that the particular composition of the medium in which adipose stromal cells are cultured affects the differentiation state of the cells. However, the effect of a particular active agent added to the medium in which stromal cells are cultured on the differentiation state of the cells was not predictable at the time of the invention. The guidance in the specification

Art Unit: 1651

provides insufficient evidence that the skilled artisan would have reasonably expected to obtain undifferentiated stem cells that retain the ability to differentiate into nerve cells, vascular cells, and bone cells from adipose tissue. The specification describes the properties of cells obtained using the instantly claimed steps on muscle tissue, but the working examples include no characterization of cells obtained from adipose tissue.

M.P.E.P. § 2164.03 reads, “The amount of guidance or direction needed to enable the invention is inversely related to the amount of knowledge in the state of the art as well as the predictability in the art. *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). The ‘amount of guidance or direction’ refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictable the art is, the less information needs to be explicitly stated in the specification. **In contrast, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail as to how to make and use the invention in order to be enabling.** See, e.g., *Chiron Corp. v. Genentech Inc.*, 363 F.3d 1247, 1254, 70 USPQ2d 1321, 1326 (Fed. Cir. 2004)...In applications directed to inventions in arts where the results are unpredictable, the disclosure of a single species usually does not provide an adequate basis to support generic claims. In cases involving unpredictable factors, such as most chemical reactions and physiological activity, more may be required.” As the above discussion illustrates, the effects of at least a few active agents on adipose stromal cells were unpredictable at the time of the invention, so addition of

Art Unit: 1651

any given active agent or combination thereof to adipose stromal cells must be considered "nascent," and the amount of guidance required is relatively high.

The specification reads, "Because the [human fat stem cells] of the present invention are of the same mesenchymal origin as the [human muscle stem cells], this also suggests that the same differentiating abilities described above contained in the hMSC are also present in the hFSC" (page 11, paragraph 5). However, this statement is not supported by evidence. Numerous diverse tissues including connective tissue, bone, cartilage, and blood, as well as the tissues that make up the circulatory and lymphatic systems, arise from mesenchyme. These tissues do not share functions with each other or with adipose and/or skeletal muscle, and they do not contain the same kinds of cells. The specification provides no evidence that all tissues of mesenchymal origin may be cultured in the instantly claimed culture medium to yield undifferentiated stem cells.

While a narrow working embodiment cannot be a sole factor in determining enablement, its limited showing, in light of the unpredictable nature of the art and the lack of direction applicants present, provides additional weight to the lack of enablement in consideration of the *Wands* factors as a whole. Thus, one of ordinary skill in the art would not have a reasonable expectation of success in using the claimed invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 2, and 7-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 is drawn to a method of making a cell that is “capable of differentiating into” several differentiated cell types, which is confusing. It is not clear under what conditions the cell yielded by the instant method can differentiate into the recited types; for example, it is not clear whether the claim encompasses methods of making cells that, when transfected with exogenous DNA, can differentiate to the recited types, or whether the cell necessarily differentiates as recited. Clarification is required.

Step (c) of claim 1 requires incubating the cells in a medium comprising “usual inorganic salts,” but the scope of this claim term is unclear. The basis for the relative term “usual” is not pointed out. Clarification is required.

Step (c) of claim 1 also recites “usual inorganic salts, natural amino acids, and vitamins necessary for the growth of mammalian cells,” which is confusing for several reasons. First, it is not clear whether the word “necessary” applies only to the term immediately preceding it (“vitamins”), to every term in the list, or some subset thereof. Furthermore, the scope of the “necessary” components is not pointed out. Finally, the claim requires that the media comprise components necessary for the growth of “mammalian cells” in general, not the specific cells yielded by the method. Clarification is required.

Finally, the steps of claim 1 as currently recited do not yield stem cells. The preamble of the claim differs in scope from the steps. Clarification is required.

Because claims 2 and 7-9 depend from indefinite claim 1 and do not clarify these points of confusion, they must also be rejected under 35 U.S.C. 112, second paragraph.

Claim 2 requires that the medium be supplemented with various components in amounts expressed as, e.g., “ng/mL,” but it is not clear how these amounts relate to the media. The claim does not require, e.g., that the medium comprise between 0.4% and 0.5% BSA or that it comprise between 5 and 20ng bFGF/mL of medium. Clarification is required. Furthermore, the word “and” should separate the last and second-to-last item in the list.

Claim 8 is confusing because it is not clear whether the steps recited therein are performed after the steps in claim 1 or whether they are meant to replace step (c) of claim 1. Clarification is required.

Steps (c1) and (c3) of claim 8 recites “the growth medium,” but claim 1 does not recite a growth medium. There is insufficient antecedent basis for this limitation in claim 8. Clarification is required.

Step (c2) of claim 8 refers to “the previous step,” but it is not clear which step is “previous,” since the claims do not require that the steps be carried out in any particular order.

No claims are allowed.

Applicant is requested to specifically point out the support for any amendments made to the disclosure in response to this Office action, including the claims (MPEP 714.02 and 2163.06). In doing so, applicant is requested to refer to pages and line numbers in the as-filed specification, **not** the published application. Due to the

Art Unit: 1651

procedure outlined in MPEP § 2163.06 for interpreting claims, it is noted that other art may be applicable under 35 U.S.C. § 102 or 35 U.S.C. § 103(a) once the aforementioned issue(s) is/are addressed.

Applicant is requested to provide a list of all copending U.S. applications that set forth similar subject matter to the present claims. A copy of such copending claims is requested in response to this Office action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lora E. Barnhart whose telephone number is 571-272-1928. The examiner can normally be reached on Monday-Thursday, 9:00am - 5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Lora E Barnhart/
Primary Examiner, Art Unit 1651